Annual CFO
-$174.88 M
+$66.24 M+27.47%
December 31, 2023
Summary
- As of February 7, 2025, CHRS annual cash flow from operations is -$174.88 million, with the most recent change of +$66.24 million (+27.47%) on December 31, 2023.
- During the last 3 years, CHRS annual CFO has fallen by -$329.03 million (-213.45%).
- CHRS annual CFO is now -213.45% below its all-time high of $154.15 million, reached on December 31, 2020.
Performance
CHRS Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$62.02 M
-$121.75 M-203.82%
September 30, 2024
Summary
- As of February 7, 2025, CHRS quarterly cash flow from operations is -$62.02 million, with the most recent change of -$121.75 million (-203.82%) on September 30, 2024.
- Over the past year, CHRS quarterly CFO has dropped by -$7.72 million (-14.21%).
- CHRS quarterly CFO is now -203.03% below its all-time high of $60.19 million, reached on June 30, 2020.
Performance
CHRS Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$61.98 M
-$7.72 M-14.22%
September 30, 2024
Summary
- As of February 7, 2025, CHRS TTM cash flow from operations is -$61.98 million, with the most recent change of -$7.72 million (-14.22%) on September 30, 2024.
- Over the past year, CHRS TTM CFO has increased by +$199.91 million (+76.33%).
- CHRS TTM CFO is now -140.21% below its all-time high of $154.15 million, reached on December 31, 2020.
Performance
CHRS TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
CHRS Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +27.5% | -14.2% | +76.3% |
| 3 y3 years | -213.4% | -59.4% | +74.7% |
| 5 y5 years | -9.8% | -59.4% | +74.7% |
CHRS Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -367.2% | +27.5% | -203.8% | +38.0% | -65.6% | +76.3% |
| 5 y | 5-year | -213.4% | +27.5% | -203.0% | +38.0% | -140.2% | +76.3% |
| alltime | all time | -213.4% | +30.8% | -203.0% | +38.0% | -140.2% | +77.7% |
Coherus BioSciences Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$62.02 M(-203.8%) | -$61.98 M(+14.2%) |
| Jun 2024 | - | $59.73 M(-227.7%) | -$54.27 M(-64.5%) |
| Mar 2024 | - | -$46.77 M(+261.5%) | -$152.92 M(-12.6%) |
| Dec 2023 | -$174.88 M(-27.5%) | -$12.94 M(-76.2%) | -$174.88 M(-33.2%) |
| Sep 2023 | - | -$54.30 M(+39.5%) | -$261.90 M(+7.0%) |
| Jun 2023 | - | -$38.91 M(-43.4%) | -$244.69 M(-4.3%) |
| Mar 2023 | - | -$68.73 M(-31.2%) | -$255.81 M(+6.1%) |
| Dec 2022 | -$241.12 M(+544.2%) | -$99.95 M(+169.5%) | -$241.12 M(+24.6%) |
| Sep 2022 | - | -$37.09 M(-25.9%) | -$193.49 M(+35.6%) |
| Jun 2022 | - | -$50.04 M(-7.4%) | -$142.69 M(+53.7%) |
| Mar 2022 | - | -$54.05 M(+3.3%) | -$92.84 M(+148.0%) |
| Dec 2021 | -$37.43 M(-124.3%) | -$52.32 M(-481.6%) | -$37.43 M(-178.0%) |
| Sep 2021 | - | $13.71 M(-7393.1%) | $48.01 M(-41.2%) |
| Jun 2021 | - | -$188.00 K(-113.8%) | $81.66 M(-42.5%) |
| Mar 2021 | - | $1.37 M(-95.9%) | $142.03 M(-7.9%) |
| Dec 2020 | $154.15 M(+443.6%) | $33.12 M(-30.0%) | $154.15 M(+11.1%) |
| Sep 2020 | - | $47.35 M(-21.3%) | $138.73 M(-5.2%) |
| Jun 2020 | - | $60.19 M(+346.6%) | $146.33 M(+48.1%) |
| Mar 2020 | - | $13.48 M(-23.9%) | $98.81 M(+248.5%) |
| Dec 2019 | $28.36 M | $17.71 M(-67.8%) | $28.36 M(-177.2%) |
| Sep 2019 | - | $54.95 M(+333.5%) | -$36.72 M(-72.7%) |
| Jun 2019 | - | $12.68 M(-122.2%) | -$134.46 M(-26.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$56.98 M(+20.3%) | -$182.66 M(+14.7%) |
| Dec 2018 | -$159.27 M(-20.5%) | -$47.36 M(+10.7%) | -$159.27 M(+12.3%) |
| Sep 2018 | - | -$42.79 M(+20.4%) | -$141.82 M(+0.9%) |
| Jun 2018 | - | -$35.53 M(+5.8%) | -$140.55 M(-12.5%) |
| Mar 2018 | - | -$33.58 M(+12.2%) | -$160.59 M(-19.8%) |
| Dec 2017 | -$200.29 M(-20.7%) | -$29.92 M(-27.9%) | -$200.29 M(-22.1%) |
| Sep 2017 | - | -$41.51 M(-25.3%) | -$257.26 M(-7.4%) |
| Jun 2017 | - | -$55.57 M(-24.2%) | -$277.69 M(+11.3%) |
| Mar 2017 | - | -$73.28 M(-15.7%) | -$249.51 M(-1.2%) |
| Dec 2016 | -$252.54 M(+133.9%) | -$86.89 M(+40.3%) | -$252.54 M(+57.8%) |
| Sep 2016 | - | -$61.95 M(+126.2%) | -$160.09 M(+1.5%) |
| Jun 2016 | - | -$27.39 M(-64.1%) | -$157.79 M(+4.3%) |
| Mar 2016 | - | -$76.32 M(-1470.9%) | -$151.24 M(+40.1%) |
| Dec 2015 | -$107.99 M(+351.3%) | $5.57 M(-109.3%) | -$107.99 M(-26.5%) |
| Sep 2015 | - | -$59.66 M(+186.3%) | -$146.84 M(+59.0%) |
| Jun 2015 | - | -$20.84 M(-37.0%) | -$92.36 M(+28.7%) |
| Mar 2015 | - | -$33.06 M(-0.7%) | -$71.73 M(+199.8%) |
| Dec 2014 | -$23.93 M(-255.1%) | -$33.28 M(+543.8%) | -$23.93 M(-355.7%) |
| Sep 2014 | - | -$5.17 M(+2282.5%) | $9.36 M(-35.6%) |
| Jun 2014 | - | -$217.00 K(-101.5%) | $14.53 M(-1.5%) |
| Mar 2014 | - | $14.74 M | $14.74 M |
| Dec 2013 | $15.42 M(-184.5%) | - | - |
| Dec 2012 | -$18.25 M | - | - |
FAQ
- What is Coherus BioSciences annual cash flow from operations?
- What is the all time high annual CFO for Coherus BioSciences?
- What is Coherus BioSciences annual CFO year-on-year change?
- What is Coherus BioSciences quarterly cash flow from operations?
- What is the all time high quarterly CFO for Coherus BioSciences?
- What is Coherus BioSciences quarterly CFO year-on-year change?
- What is Coherus BioSciences TTM cash flow from operations?
- What is the all time high TTM CFO for Coherus BioSciences?
- What is Coherus BioSciences TTM CFO year-on-year change?
What is Coherus BioSciences annual cash flow from operations?
The current annual CFO of CHRS is -$174.88 M
What is the all time high annual CFO for Coherus BioSciences?
Coherus BioSciences all-time high annual cash flow from operations is $154.15 M
What is Coherus BioSciences annual CFO year-on-year change?
Over the past year, CHRS annual cash flow from operations has changed by +$66.24 M (+27.47%)
What is Coherus BioSciences quarterly cash flow from operations?
The current quarterly CFO of CHRS is -$62.02 M
What is the all time high quarterly CFO for Coherus BioSciences?
Coherus BioSciences all-time high quarterly cash flow from operations is $60.19 M
What is Coherus BioSciences quarterly CFO year-on-year change?
Over the past year, CHRS quarterly cash flow from operations has changed by -$7.72 M (-14.21%)
What is Coherus BioSciences TTM cash flow from operations?
The current TTM CFO of CHRS is -$61.98 M
What is the all time high TTM CFO for Coherus BioSciences?
Coherus BioSciences all-time high TTM cash flow from operations is $154.15 M
What is Coherus BioSciences TTM CFO year-on-year change?
Over the past year, CHRS TTM cash flow from operations has changed by +$199.91 M (+76.33%)